Bristol-Myers Squibb Co
Pharmaceuticals
Bristol-Myers Squibb Co (BMY) Stock News
The latest BMY headlines and market coverage — 5 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers Squibb (BMY) has been a trending stock but faces headwinds with shares down 11.1% over the past month. While the company maintains a Zacks Rank #3 (Hold) rating and trades at a valuation discount to peers, earnings estimates have declined 3.6% over the last 30 days. The company has a strong track record of beating consensus estimates but faces modest revenue growth projections of 3.4% for the current fiscal year.
- Zacks Investment Research·
BMY Reports Mixed Phase III Trial Results, Stock Down
Bristol Myers Squibb announced mixed Phase III results for admilparant in idiopathic pulmonary fibrosis, meeting its primary endpoint only at the 60-mg dose while failing at 120-mg, causing the stock to decline 2.6%. However, the company reported positive Phase III results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, demonstrating statistically significant improvement in progression-free survival. The mixed outcomes reflect uncertainty about admilparant's dose consistency despite favorable safety profiles.
- Zacks Investment Research·
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers Squibb (BMY) is receiving significant investor attention. The stock has declined 6.1% over the past month, underperforming the S&P 500. However, the company maintains a Zacks Rank #2 (Buy) rating based on positive earnings estimate revisions and strong recent performance, with the stock trading at a valuation discount to peers. BMY beat consensus estimates in the last four quarters with an EPS surprise of +28.3% and revenue surprise of +11.15%.
- Zacks Investment Research·
BMY vs. ARGX: Which Stock Is the Better Value Option?
Bristol Myers Squibb (BMY) is positioned as a superior value opportunity compared to Argenex SE (ARGX) in the biomedical and genetics sector. BMY has a Zacks Rank of #2 (Buy) with a forward P/E of 9.10 and Value grade of A, while ARGX has a Zacks Rank of #3 (Hold) with a forward P/E of 34.19 and Value grade of C. BMY's lower valuation metrics and stronger earnings outlook make it the more attractive value play.
- Zacks Investment Research·
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.